This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
public health | 1050 |
case report | 994 |
confirmed cases | 818 |
mean age | 789 |
novel coronavirus | 727 |
bone marrow | 662 |
lymph node | 656 |
one patient | 646 |
years old | 629 |
united states | 617 |
acute respiratory | 611 |
risk factors | 610 |
study design | 591 |
lymph nodes | 582 |
case studies | 543 |
statistically significant | 543 |
coronavirus disease | 525 |
infectious diseases | 522 |
author funder | 513 |
granted medrxiv | 513 |
two groups | 495 |
copyright holder | 485 |
background case | 481 |
significant difference | 470 |
respiratory syndrome | 469 |
differential diagnosis | 467 |
contact tracing | 464 |
health care | 452 |
minimally invasive | 448 |
incubation period | 448 |
breast cancer | 446 |
mg dl | 442 |
hospital stay | 441 |
intensive care | 440 |
patients underwent | 439 |
one case | 437 |
significantly higher | 433 |
control group | 428 |
two patients | 423 |
social distancing | 420 |
severe acute | 414 |
performed using | 409 |
abdominal pain | 409 |
new cases | 402 |
aft er | 401 |
ct scan | 400 |
year old | 395 |
two cases | 390 |
design method | 387 |
made available | 386 |
median age | 384 |
mg kg | 382 |
old male | 382 |
results finding | 375 |
infectious disease | 374 |
total number | 374 |
significant differences | 361 |
weight loss | 357 |
international license | 350 |
cell carcinoma | 347 |
infected cases | 346 |
version posted | 344 |
imaging findings | 343 |
doc id | 338 |
cord uid | 338 |
mortality rate | 337 |
computed tomography | 335 |
old female | 329 |
retrospective study | 326 |
close contacts | 322 |
soft tissue | 319 |
reproduction number | 314 |
age group | 312 |
tumor cells | 311 |
may also | 307 |
first case | 301 |
world health | 300 |
patients undergoing | 298 |
reported cases | 294 |
blood loss | 292 |
high risk | 290 |
small bowel | 290 |
operative time | 290 |
trauma patients | 286 |
present study | 277 |
least one | 277 |
symptom onset | 275 |
index case | 274 |
hearing loss | 271 |
surgical treatment | 270 |
laparoscopic surgery | 267 |
clinical features | 266 |
prostate cancer | 266 |
emergency department | 265 |
age groups | 262 |
peripheral blood | 262 |
fatality rate | 261 |
long term | 260 |
mr imaging | 260 |
health organization | 255 |
case reports | 253 |
control measures | 251 |
signifi cant | 249 |
old woman | 249 |
statistical analysis | 249 |
physical examination | 249 |
per day | 247 |
three patients | 246 |
respiratory distress | 246 |
magnetic resonance | 245 |
peer review | 245 |
laparoscopic approach | 245 |
colorectal cancer | 243 |
university hospital | 243 |
adverse events | 240 |
red blood | 239 |
renal failure | 238 |
medrxiv preprint | 238 |
respiratory tract | 237 |
care unit | 236 |
increased risk | 234 |
gastric cancer | 233 |
severe cases | 233 |
four patients | 232 |
postoperative complications | 231 |
cases per | 229 |
bariatric surgery | 227 |
hong kong | 226 |
image quality | 226 |
attack rate | 225 |
allergic rhinitis | 225 |
disease control | 225 |
risk factor | 223 |
clinical presentation | 222 |
one year | 222 |
case fatality | 221 |
clinical characteristics | 220 |
specific ige | 219 |
old man | 216 |
stem cell | 214 |
pediatric patients | 214 |
cd cd | 213 |
urinary tract | 212 |
nervous system | 212 |
secondary cases | 211 |
patients treated | 206 |
clinical signs | 206 |
three cases | 205 |
growth rate | 205 |
squamous cell | 205 |
significantly lower | 205 |
imported cases | 204 |
blood cell | 203 |
flow cytometry | 202 |
medical center | 202 |
logistic regression | 201 |
five patients | 200 |
rectal cancer | 200 |
case series | 200 |
ng ml | 199 |
cell lymphoma | 198 |
gastric bypass | 198 |
consecutive patients | 197 |
average age | 197 |
hernia repair | 196 |
lung cancer | 195 |
abdominal wall | 195 |
blood bank | 194 |
important role | 192 |
surgical intervention | 192 |
may occur | 192 |
patients received | 192 |
respiratory failure | 192 |
leydig cells | 189 |
whole blood | 189 |
family history | 188 |
postoperative day | 187 |
clinical course | 187 |
mechanical ventilation | 186 |
bile duct | 186 |
last years | 186 |
blood cells | 182 |
regression analysis | 181 |
syndrome coronavirus | 180 |
clinical symptoms | 180 |
methods materials | 177 |
spinal cord | 176 |
sleeve gastrectomy | 176 |
gene expression | 175 |
cohort study | 175 |
sertoli cells | 174 |
smooth muscle | 174 |
cancer patients | 174 |
surveillance system | 174 |
general population | 173 |
close contact | 173 |
confirmed case | 172 |
electron microscopy | 172 |
year period | 171 |
exome sequencing | 170 |
retrospective analysis | 170 |
type i | 169 |
study period | 169 |
health system | 169 |
lung disease | 169 |
clinical findings | 168 |
medical history | 168 |
associated case | 168 |
blood flow | 166 |
overall survival | 165 |
large number | 164 |
results suggest | 164 |
germ cell | 164 |
central nervous | 163 |
patients showed | 163 |
pg ml | 162 |
family members | 162 |
cell lines | 162 |
operation time | 162 |
renal function | 161 |
surgical procedures | 161 |
prospective study | 161 |
ct scans | 160 |
seminiferous tubules | 160 |
protein expression | 159 |
primary immunodeficiency | 159 |
blood pressure | 158 |
resonance imaging | 158 |
new york | 158 |
systematic review | 157 |
fi rst | 157 |
medical records | 157 |
positive cases | 157 |
cumulative number | 157 |
case definition | 156 |
confirmed covid | 156 |
laparoscopic cholecystectomy | 156 |
chest ct | 156 |
within days | 156 |
patients without | 155 |
age range | 155 |
white matter | 155 |
retrospective review | 154 |
time period | 154 |
general surgery | 153 |
clinical practice | 150 |
gold standard | 150 |
examination revealed | 149 |
standard deviation | 148 |
heart disease | 148 |
mortality rates | 147 |
th ere | 147 |
predictive value | 147 |
clinical manifestations | 146 |
acute appendicitis | 146 |
cd cells | 146 |
middle east | 146 |
chain reaction | 146 |
tested positive | 146 |
leydig cell | 145 |
type ii | 145 |
two weeks | 145 |
results findings | 144 |
gastrointestinal tract | 143 |
serial interval | 143 |
side effects | 143 |
retrospectively reviewed | 142 |
statistical significance | 142 |
polymerase chain | 142 |
even though | 142 |
distress syndrome | 142 |
early diagnosis | 141 |
primary case | 141 |
blood donors | 141 |
patient underwent | 141 |
high grade | 141 |
significantly different | 140 |
tumor size | 140 |
case patient | 140 |
clinical data | 140 |
respiratory symptoms | 139 |
design methods | 139 |
signal intensity | 139 |
two different | 139 |
growth factor | 139 |
adult patients | 138 |
transmission dynamics | 138 |
skin prick | 137 |
asymptomatic cases | 137 |
informed consent | 137 |
critical care | 137 |
two years | 136 |
old girl | 136 |
case study | 136 |
cases reported | 136 |
high resolution | 136 |
blood products | 135 |
per year | 135 |
surgical procedure | 135 |
six patients | 135 |
conservative treatment | 135 |
inclusion criteria | 135 |
significant increase | 135 |
population density | 134 |
critically ill | 134 |
infected individuals | 134 |
first time | 134 |
south korea | 133 |
abstract case | 133 |
hubei province | 133 |
may lead | 133 |
basic reproduction | 133 |
colon cancer | 133 |
blood samples | 132 |
real time | 132 |
epithelial cells | 132 |
report text | 132 |
sample size | 131 |
patients presented | 131 |
respiratory infections | 131 |
cystic fibrosis | 131 |
pregnant women | 130 |
analysis showed | 130 |
immune system | 129 |
significant correlation | 129 |
blood transfusion | 129 |
bowel obstruction | 129 |
diabetes mellitus | 129 |
low grade | 129 |
contrast enhancement | 129 |
may result | 129 |
old boy | 129 |
patient presented | 129 |
data collection | 128 |
operating room | 128 |
wide range | 128 |
multiple myeloma | 128 |
multivariate analysis | 128 |
immune response | 127 |
small cell | 127 |
prognostic factors | 127 |
influenza virus | 127 |
extremely rare | 126 |
per million | 126 |
time series | 126 |
study group | 126 |
diagnostic accuracy | 126 |
cell proliferation | 125 |
previously reported | 125 |
see table | 125 |
female patient | 125 |
infection control | 125 |
blood vessels | 125 |
higher risk | 125 |
autosomal recessive | 124 |
air pollution | 124 |
complication rate | 124 |
inguinal hernia | 124 |
sertoli cell | 124 |
four cases | 124 |
united kingdom | 123 |
red cell | 123 |
body mass | 123 |
coronary artery | 122 |
spiral ct | 122 |
early stage | 122 |
virus infection | 122 |
learning curve | 122 |
suspected cases | 121 |
among patients | 121 |
may cause | 121 |
one week | 121 |
connective tissue | 121 |
within hours | 120 |
food allergy | 120 |
mg ml | 120 |
male patient | 120 |
generation sequencing | 120 |
elderly patients | 120 |
will also | 118 |
patients admitted | 118 |
confidence interval | 118 |
free survival | 118 |
blood center | 118 |
sir model | 117 |
two months | 117 |
cell count | 117 |
small intestine | 117 |
many cases | 117 |
different types | 117 |
atopic dermatitis | 117 |
included patients | 117 |
avian influenza | 117 |
significantly increased | 116 |
developing countries | 116 |
symptomatic cases | 116 |
patient care | 116 |
viral infections | 116 |
age years | 116 |
respiratory disease | 116 |
genetic testing | 116 |
renal cell | 115 |
trauma center | 115 |
scoring system | 115 |
mass index | 115 |
determine whether | 115 |
signifi cantly | 115 |
rights reserved | 114 |
congenital heart | 114 |
underwent laparoscopic | 114 |
stem cells | 114 |
one month | 114 |
bladder cancer | 114 |
platelet count | 114 |
months later | 113 |
surgical management | 113 |
case numbers | 113 |
small number | 113 |
replacement therapy | 112 |
surgical resection | 112 |
aged years | 112 |
renal disease | 112 |
fatality rates | 112 |
patients aged | 112 |
invasive surgery | 112 |
personal protective | 112 |
may help | 112 |
hiatal hernia | 111 |
learning objectives | 111 |
patients presenting | 111 |
clinical outcome | 111 |
robotic surgery | 111 |
pleural effusion | 111 |
literature review | 110 |
neoplastic cells | 110 |
normal range | 110 |
posted may | 110 |
analysis revealed | 110 |
th day | 110 |
cases showed | 110 |
mean follow | 109 |
primary care | 109 |
care workers | 109 |
rift valley | 109 |
significantly associated | 109 |
seven patients | 109 |
cell tumors | 109 |
eight patients | 109 |
plasma cell | 108 |
physical distancing | 108 |
next generation | 108 |
control study | 108 |
emergency surgery | 108 |
transmission rate | 108 |
abdominal cavity | 108 |
nine patients | 107 |
widely used | 107 |
average number | 107 |
rete testis | 107 |
five cases | 107 |
exponential growth | 107 |
valley fever | 107 |
white blood | 106 |
three months | 106 |
open surgery | 106 |
tract infections | 106 |
european countries | 106 |
results show | 106 |
recurrent infections | 105 |
poor prognosis | 104 |
ct findings | 104 |
autosomal dominant | 104 |
commonly used | 104 |
blood group | 104 |
radical prostatectomy | 104 |
study aimed | 103 |
breast carcinoma | 103 |
preliminary results | 103 |
cardiac surgery | 103 |
body weight | 103 |
six months | 102 |
chart review | 102 |
previous studies | 102 |
node dissection | 102 |
plasma cells | 102 |
positive correlation | 102 |
protective equipment | 101 |
month period | 101 |
data analysis | 101 |
contrast agent | 101 |
machine learning | 101 |
high levels | 101 |
fi ndings | 100 |
east respiratory | 100 |
group i | 99 |
illness onset | 99 |
anastomotic leak | 99 |
data collected | 99 |
case presentation | 99 |
abdominal trauma | 99 |
days later | 99 |
retrospective cohort | 99 |
many countries | 98 |
total population | 98 |
heart failure | 98 |
one hundred | 98 |
disease surveillance | 98 |
nucleic acid | 98 |
odds ratio | 97 |
test results | 97 |
pulmonary edema | 97 |
contrast enhanced | 97 |
surgical technique | 97 |
different countries | 97 |
upper respiratory | 96 |
cell tumor | 96 |
examination showed | 96 |
postoperative period | 96 |
three groups | 96 |
foreign body | 95 |
cases may | 95 |
much higher | 95 |
clinical trials | 95 |
combined immunodeficiency | 95 |
evaluated using | 95 |
case finding | 95 |
household contacts | 95 |
clinical examination | 95 |
cell carcinomas | 95 |
recent studies | 94 |
active cases | 94 |
organ failure | 94 |
clinical diagnosis | 94 |
assessed using | 93 |
nk cells | 93 |
urinary bladder | 93 |
final diagnosis | 93 |
study included | 93 |
patients diagnosed | 93 |
hospitalized patients | 93 |
germ cells | 93 |
hepatocellular carcinoma | 93 |
case history | 93 |
recent years | 93 |
also found | 93 |
grass pollen | 92 |
positive cells | 92 |
nk cell | 92 |
regression model | 92 |
imaging features | 92 |
identifi ed | 92 |
emergency room | 92 |
brain injury | 92 |
case definitions | 92 |
median follow | 92 |
patients died | 91 |
iu ml | 91 |
medical treatment | 91 |
cell transplantation | 91 |
patients may | 91 |
per capita | 91 |
clinical outcomes | 91 |
health authorities | 91 |
endothelial cells | 91 |
radiation dose | 91 |
decision making | 90 |
high incidence | 90 |
histological examination | 90 |
common cause | 90 |
well known | 90 |
slice thickness | 90 |
immune deficiency | 90 |
local recurrence | 90 |
medical university | 90 |
cases will | 90 |
analyzed using | 90 |
deaths per | 89 |
early phase | 89 |
significant improvement | 89 |
whole exome | 89 |
lung function | 89 |
general hospital | 89 |
term follow | 89 |
situ hybridization | 89 |
survival rate | 89 |
healthy controls | 89 |
laboratory tests | 89 |
infection rate | 88 |
sensorineural hearing | 88 |
diagnostic criteria | 88 |
coronavirus pneumonia | 88 |
linear regression | 88 |
abdominal ct | 88 |
laboratory findings | 88 |
immunohistochemical staining | 88 |
mean time | 88 |
distancing measures | 88 |
study aims | 88 |
corona virus | 88 |
early stages | 88 |
data suggest | 87 |
demographic data | 87 |
gastroesophageal reflux | 87 |
total cases | 87 |
cumulative cases | 87 |
patients developed | 87 |
serum levels | 87 |
radiation exposure | 86 |
results showed | 86 |
rib fractures | 86 |
disaster period | 86 |
children aged | 86 |
needle aspiration | 86 |
natural history | 86 |
female patients | 86 |
first two | 86 |
selected patients | 86 |
imaging modalities | 86 |
developmental delay | 86 |
monoclonal antibodies | 85 |
bowel disease | 85 |
three days | 85 |
quality control | 85 |
attack rates | 85 |
male patients | 85 |
study showed | 85 |
may provide | 85 |
node metastasis | 85 |
well tolerated | 85 |
see chapter | 85 |
liver disease | 85 |
postoperative course | 85 |
right side | 85 |
death rate | 84 |
factors associated | 84 |
high level | 84 |
inflammatory bowel | 84 |
results indicate | 84 |
ml min | 83 |
mr images | 83 |
reproductive number | 83 |
ct imaging | 83 |
blood supply | 83 |
vast majority | 83 |
inflammatory response | 83 |
first days | 83 |
vena cava | 83 |
blunt trauma | 83 |
posted september | 83 |
viral load | 82 |
reactive protein | 82 |
indocyanine green | 82 |
young children | 82 |
data set | 82 |
general anesthesia | 82 |
saudi arabia | 82 |
portal vein | 82 |
paraffin embedded | 82 |
ct angiography | 82 |
blood components | 82 |
case isolation | 82 |
injury severity | 82 |
gestational age | 82 |
postoperative pain | 82 |
travel restrictions | 82 |
negative pressure | 81 |
lung injury | 81 |
healthcare workers | 81 |
function tests | 81 |
acute renal | 81 |
neural network | 81 |
nan doi | 81 |
years ago | 81 |
pediatric population | 81 |
may play | 81 |
overall mortality | 81 |
poorly differentiated | 81 |
hemolytic anemia | 80 |
virus disease | 80 |
epidemic curve | 80 |
case patients | 80 |
emerging infectious | 80 |
surgical approach | 80 |
effective treatment | 80 |
chest wall | 80 |
cd expression | 80 |
ill patients | 80 |
young adults | 80 |
viral infection | 80 |
monoclonal antibody | 80 |
term outcomes | 80 |
helical ct | 80 |
significant reduction | 80 |
carotid artery | 79 |
medical care | 79 |
time pcr | 79 |
surgical excision | 79 |
surveillance systems | 79 |
household members | 79 |
drinking water | 79 |
positive results | 79 |
hematopoietic stem | 79 |
bacterial infections | 79 |
clinically significant | 79 |
nitric oxide | 78 |
epidemic control | 78 |
functional outcome | 78 |
diagnosed cases | 78 |
previously described | 78 |
false positive | 78 |
two days | 78 |
mathematical model | 78 |
low risk | 77 |
clinical management | 77 |
success rate | 77 |
defi ciency | 77 |
left side | 77 |
total ige | 77 |
rbc units | 77 |
national health | 77 |
cell lung | 77 |
surg endosc | 77 |
turkey objective | 77 |
upper gi | 77 |
observational study | 77 |
may include | 77 |
prognostic factor | 77 |
first year | 77 |
early detection | 76 |
common variable | 76 |
recurrence rate | 76 |
patient developed | 76 |
kg day | 76 |
immune dysregulation | 76 |
scan showed | 76 |
diagnostic tool | 76 |
prick test | 76 |
case counts | 76 |
treatment option | 76 |
sporadic cases | 76 |
defi ned | 76 |
pulmonary artery | 76 |
herd immunity | 76 |
infectious period | 76 |
commercially available | 76 |
anastomotic leakage | 75 |
diff erence | 75 |
infl uenza | 75 |
epidemiological characteristics | 75 |
blood product | 75 |
seasonal influenza | 75 |
million people | 75 |
patient died | 75 |
antibiotic therapy | 75 |
clinical case | 75 |
pharmaceutical interventions | 75 |
also performed | 75 |
colorectal surgery | 75 |
patients receiving | 75 |
clinical trial | 75 |
measured using | 75 |
confidence intervals | 75 |
ten patients | 75 |
severity score | 75 |
ml kg | 75 |
imaging modality | 74 |
respiratory illness | 74 |
severe disease | 74 |
wall thickening | 74 |
gleason score | 74 |
first cases | 74 |
blood count | 74 |
remaining patients | 74 |
three different | 74 |
pulmonary function | 74 |
procedure details | 74 |
ebola virus | 74 |
short term | 74 |
month follow | 74 |
pulmonary embolism | 74 |
weighted images | 74 |
information system | 73 |
healthcare system | 73 |
least two | 73 |
escherichia coli | 73 |
local transmission | 73 |
patient characteristics | 73 |
contact rate | 73 |
pilot study | 73 |
transfusion medicine | 73 |
major complications | 73 |
right upper | 73 |
food supply | 73 |
microscopic examination | 73 |
person transmission | 73 |
high frequency | 73 |
clinical history | 73 |
prick tests | 73 |
infected people | 72 |
less likely | 72 |
may require | 72 |
among children | 72 |
ct images | 72 |
clinical information | 72 |
flow cytometric | 72 |
significant decrease | 72 |
tertiary care | 72 |
within normal | 72 |
south africa | 72 |
cell line | 72 |
positive patients | 72 |
septic shock | 72 |
pulmonary hypertension | 72 |
high mortality | 72 |
per patient | 72 |
mean number | 72 |
respiratory viruses | 72 |
recovered cases | 71 |
mainland china | 71 |
less common | 71 |
medical record | 71 |
adverse effects | 71 |
core biopsy | 71 |
contrast medium | 71 |
adjuvant chemotherapy | 71 |
heart rate | 71 |
data sets | 71 |
medical students | 71 |
primary cases | 71 |
findings suggest | 70 |
acute abdomen | 70 |
reuse allowed | 70 |
will help | 70 |
compound heterozygous | 70 |
stage i | 70 |
average time | 70 |
urothelial carcinoma | 70 |
false negative | 70 |
respiratory infection | 70 |
selected cases | 70 |
allowed without | 70 |
treatment options | 70 |
without permission | 70 |
clinically relevant | 70 |
mri findings | 70 |
patient age | 70 |
cell cycle | 69 |
young people | 69 |
sore throat | 69 |
mrna expression | 69 |
oxidative stress | 69 |
median time | 69 |
table shows | 69 |
investigation results | 69 |
health services | 69 |
good results | 69 |
group ii | 69 |
hemorrhagic fever | 69 |
collected data | 69 |
significantly reduced | 69 |
effective reproduction | 69 |
also known | 69 |
local health | 69 |
situation report | 69 |
treated patients | 69 |
biopsy specimens | 69 |
skin lesions | 69 |
pathological findings | 69 |
population size | 69 |
eff ects | 68 |
sensitivity analysis | 68 |
grade iii | 68 |
six cases | 68 |
operating time | 68 |
past years | 68 |
tract infection | 68 |
imaging studies | 68 |
study population | 68 |
north america | 68 |
kidney disease | 68 |
adverse reactions | 68 |
survival rates | 68 |
lower respiratory | 68 |
radiation therapy | 68 |
expression levels | 68 |
pediatric radiology | 68 |
health department | 68 |
intestinal obstruction | 68 |
risk assessment | 68 |
lower extremity | 68 |
may contribute | 68 |
modelling study | 68 |
patients suffering | 68 |
one third | 68 |
publicly available | 68 |
interstitial lung | 68 |
daily cases | 68 |
high rate | 68 |
cell types | 67 |
univariate analysis | 67 |
lupus erythematosus | 67 |
cervical spine | 67 |
post operative | 67 |
cd positive | 67 |
year survival | 67 |
disease transmission | 67 |
higher incidence | 67 |
massive transfusion | 67 |
hospitalized cases | 67 |
mean operative | 67 |
spindle cells | 67 |
disease activity | 67 |
correct diagnosis | 67 |
conversion rate | 67 |
acquired pneumonia | 67 |
high prevalence | 67 |
underwent surgery | 67 |
health systems | 67 |
community transmission | 67 |
blood volume | 67 |
also observed | 67 |
patients required | 67 |
minimal invasive | 66 |
patients infected | 66 |
infected patients | 66 |
also used | 66 |
rare case | 66 |
air pollutants | 66 |
gonadal dysgenesis | 66 |
metastatic disease | 66 |
liver function | 66 |
tissue samples | 66 |
invasive approach | 66 |
one day | 66 |
healthy volunteers | 66 |
clinical improvement | 66 |
first reported | 66 |
hospital beds | 66 |
spatial resolution | 66 |
significantly decreased | 66 |
autoimmune diseases | 66 |
study shows | 66 |
discharged home | 66 |
obese patients | 65 |
suspected covid | 65 |
term results | 65 |
mg day | 65 |
active surveillance | 65 |
node metastases | 65 |
cvid patients | 65 |
incisional hernia | 65 |
tumour cells | 65 |
asymptomatic patients | 65 |
whole body | 65 |
relatively low | 65 |
mental health | 65 |
complication rates | 65 |
liver resection | 65 |
successfully treated | 65 |
seir model | 65 |
tunica albuginea | 65 |
intravenous immunoglobulin | 65 |
diffuse large | 65 |
right lower | 65 |
fine needle | 65 |
transfusion service | 65 |
mild symptoms | 64 |
antibody deficiency | 64 |
large cell | 64 |
granulomatous disease | 64 |
related complications | 64 |
gastrointestinal stromal | 64 |
lung tissue | 64 |
light microscopy | 64 |
confi rmed | 64 |
first step | 64 |
response rate | 64 |
five years | 64 |
three years | 64 |
reported case | 64 |
low dose | 64 |
per month | 64 |
correlation coefficient | 64 |
variable immunodeficiency | 64 |
disease caused | 64 |
first months | 64 |
breast carcinomas | 64 |
mild cases | 64 |
western blot | 64 |
available data | 63 |
traumatic brain | 63 |
cystic duct | 63 |
birth weight | 63 |
showed significant | 63 |
amino acid | 63 |
may present | 63 |
old patient | 63 |
acute cholecystitis | 63 |
kawasaki disease | 63 |
intellectual disability | 63 |
contrast agents | 63 |
red zones | 63 |
house dust | 63 |
mean duration | 63 |
allergic reactions | 63 |
right hemicolectomy | 63 |
positive predictive | 63 |
better understand | 63 |
laparoscopic sleeve | 63 |
fetal mri | 63 |
epidemiological data | 63 |
also showed | 63 |
ovarian cancer | 63 |
significant relationships | 63 |
diagnostic value | 63 |
high dose | 63 |
cell counts | 63 |
contrast media | 63 |
interquartile range | 63 |
acute phase | 63 |
lung biopsy | 62 |
multislice ct | 62 |
many patients | 62 |
prognostic significance | 62 |
retrospective chart | 62 |
primary outcome | 62 |
prognostic value | 62 |
cancer cells | 62 |
immunohistochemical analysis | 62 |
operative complications | 62 |
mast cells | 62 |
otitis media | 62 |
chest pain | 62 |
hospital mortality | 62 |
definitive diagnosis | 62 |
primary tumor | 62 |
accurate diagnosis | 62 |
single center | 62 |
often associated | 62 |
mathematical models | 62 |
doubling time | 62 |
cell lymphomas | 62 |
detection rate | 62 |
icu beds | 61 |
past medical | 61 |
national institute | 61 |
time interval | 61 |
trauma care | 61 |
months post | 61 |
disease cases | 61 |
patient demographics | 61 |
partial nephrectomy | 61 |
significantly improved | 61 |
single case | 61 |
electronic medical | 61 |
one study | 61 |
second case | 61 |
ventilation rate | 61 |
american college | 61 |
several studies | 61 |
total gastrectomy | 61 |
anterior resection | 60 |
clinical suspicion | 60 |
cell receptor | 60 |
regression models | 60 |
eff ective | 60 |
differential equations | 60 |
pandemic influenza | 60 |
foreign bodies | 60 |
open reduction | 60 |
environmental factors | 60 |
patient population | 60 |
cant diff | 60 |
ige levels | 60 |
current study | 60 |
march th | 60 |
sars cases | 60 |
myocardial infarction | 60 |
early onset | 59 |
transplant recipients | 59 |
internal fixation | 59 |
immunohistochemical expression | 59 |
blood donor | 59 |
authors declare | 59 |
chronic inflammation | 59 |
travel history | 59 |
testicular torsion | 59 |
clinical studies | 59 |
mri showed | 59 |
symptomatic patients | 59 |
diagnostic imaging | 59 |
medical staff | 59 |
chest radiograph | 59 |
common bile | 59 |
multiple organ | 59 |
immunohistochemical study | 59 |
lung adenocarcinoma | 59 |
may represent | 59 |
red cells | 59 |
color doppler | 59 |
patients reported | 59 |
low levels | 59 |
liver injury | 59 |
year follow | 59 |
death toll | 59 |
postoperative morbidity | 59 |
negative results | 59 |
negative predictive | 59 |
mental retardation | 59 |
disease severity | 58 |
transverse colon | 58 |
disease progression | 58 |
radiological findings | 58 |
internal hernia | 58 |
exact test | 58 |
wound infection | 58 |
complete response | 58 |
interventional radiology | 58 |
unknown etiology | 58 |
locally advanced | 58 |
vas deferens | 58 |
human transmission | 58 |
gastric mucosa | 58 |
weeks later | 58 |
specific igg | 58 |
nephrotic syndrome | 58 |
wide variety | 58 |
disease spread | 58 |
dust mite | 58 |
corpus callosum | 58 |
reflux disease | 58 |
antibiotic treatment | 58 |
lamina propria | 57 |
missing data | 57 |
spindle cell | 57 |
also reported | 57 |
female ratio | 57 |
liver transplantation | 57 |
supplementary material | 57 |
coronavirus infection | 57 |
primary immunodeficiencies | 57 |
term outcome | 57 |
igg levels | 57 |
pet ct | 57 |
three weeks | 57 |
cells ul | 57 |
dna methylation | 57 |
control groups | 57 |
nasal spray | 57 |
per week | 57 |
mitotic activity | 57 |
underlying disease | 57 |
done using | 57 |
severe respiratory | 57 |
red zone | 57 |
upper gastrointestinal | 57 |
staphylococcus aureus | 57 |
determined using | 57 |
patients requiring | 57 |
dress dihs | 57 |
retrospectively analyzed | 57 |
transmission risk | 57 |
bowel wall | 56 |
estimated blood | 56 |
salivary gland | 56 |
liver metastases | 56 |
two main | 56 |
respiratory specimens | 56 |
mononuclear cells | 56 |
stent placement | 56 |
developed countries | 56 |
hiv infection | 56 |
global health | 56 |
ulcerative colitis | 56 |
superior mesenteric | 56 |
potential risk | 56 |
cases among | 56 |
care facilities | 56 |
useful tool | 56 |
positive test | 56 |
independent risk | 56 |
sigmoid colon | 56 |
air quality | 56 |
remains unclear | 56 |
surgical specimens | 56 |
biopsy showed | 56 |
clear cell | 56 |
testicular biopsy | 56 |
pulmonary disease | 56 |
head trauma | 56 |
physical exam | 55 |
future studies | 55 |
soft tissues | 55 |
obtained using | 55 |
analysis using | 55 |
median survival | 55 |
antibody screen | 55 |
logistic model | 55 |
may develop | 55 |
index cases | 55 |
fi nding | 55 |
airborne pathogen | 55 |
venous thrombosis | 55 |
short stature | 55 |
mast cell | 55 |
square test | 55 |
long time | 55 |
imaging techniques | 55 |
diagnostic laparoscopy | 55 |
complications occurred | 55 |
ionizing radiation | 55 |
acute pancreatitis | 55 |
clinical significance | 55 |
older age | 55 |
wide spectrum | 55 |
hospital admission | 55 |
iron deficiency | 55 |
adipose tissue | 55 |
cov infection | 55 |
sickle cell | 55 |
less frequently | 54 |
cell death | 54 |
will discuss | 54 |
biopsy revealed | 54 |
gi tract | 54 |
independent prognostic | 54 |
abdominal ultrasound | 54 |
hepatic artery | 54 |
quality improvement | 54 |
laboratory data | 54 |
grade i | 54 |
ai ethics | 54 |
surveillance data | 54 |
giant cells | 54 |
health interventions | 54 |
cancer surgery | 54 |
first described | 54 |
susceptible population | 54 |
first confirmed | 54 |
splenic injury | 54 |
patient received | 54 |
lower bound | 54 |
flow rate | 54 |
first group | 54 |
percutaneous drainage | 54 |
procedures performed | 54 |
asymptomatic infection | 54 |
brain mri | 54 |
operative day | 54 |
transfusion reactions | 54 |
differential diagnoses | 54 |
significant impact | 54 |
juvenile idiopathic | 54 |
health workers | 54 |
rhce ce | 54 |
sanger sequencing | 54 |
significantly less | 54 |
social interaction | 54 |
back pain | 54 |
paediatric patients | 54 |
household transmission | 53 |
chest radiographs | 53 |
clinical evaluation | 53 |
laparoscopic repair | 53 |
dose reduction | 53 |
skin testing | 53 |
will require | 53 |
health conditions | 53 |
broad spectrum | 53 |
within months | 53 |
cell hyperplasia | 53 |
south america | 53 |
clinical response | 53 |
excessive pricing | 53 |
calculated using | 53 |
immunoglobulin replacement | 53 |
abdominal surgery | 53 |
elective surgery | 53 |
remaining cases | 53 |
mean hospital | 53 |
early childhood | 53 |
similar results | 53 |
rheumatoid arthritis | 53 |
months old | 53 |
direct contact | 53 |
rare cases | 53 |
symptom score | 53 |
complete blood | 53 |
daily number | 53 |
also present | 53 |
times higher | 53 |
infectious agents | 53 |
copy number | 53 |
additional information | 53 |
severe combined | 53 |
well established | 53 |
patients will | 53 |
working group | 53 |
cruise ship | 53 |
skin test | 53 |
medical school | 53 |
first week | 52 |
second group | 52 |
respiratory samples | 52 |
higher rate | 52 |
underwent surgical | 52 |
mental status | 52 |
red cross | 52 |
wound healing | 52 |
time spent | 52 |
left upper | 52 |
genomic dna | 52 |
precocious puberty | 52 |
serum samples | 52 |
pictorial review | 52 |
histological features | 52 |
shock syndrome | 52 |
tyrosine kinase | 52 |
elevated serum | 52 |
adrenal gland | 52 |
risk groups | 52 |
surveillance hospital | 52 |
infection risk | 52 |
autoimmune disease | 52 |
idiopathic arthritis | 52 |
grade ii | 52 |
life expectancy | 52 |
treated conservatively | 52 |
new coronavirus | 52 |
based surveillance | 52 |
lower limb | 52 |
mri brain | 52 |
femoral head | 52 |
surgical outcomes | 52 |
controlled trial | 52 |
surgical site | 52 |
second wave | 52 |
previously healthy | 52 |
less severe | 51 |
increasing number | 51 |
clinical stage | 51 |
folic acid | 51 |
much less | 51 |
disease prevention | 51 |
immunodeficiency virus | 51 |
statistically signifi | 51 |
patient safety | 51 |
cutaneous lymphoma | 51 |
communicable diseases | 51 |
skin tests | 51 |
younger patients | 51 |
inflammatory infiltrate | 51 |
higher levels | 51 |
lockdown measures | 51 |
two independent | 51 |
mean value | 51 |
positive samples | 51 |
bacterial infection | 51 |
staple line | 51 |
trauma registry | 51 |
patients referred | 51 |
femoral neck | 51 |
control subjects | 51 |
susceptible individuals | 51 |
distant metastasis | 51 |
clinical presentations | 51 |
blood tests | 51 |
results obtained | 51 |
prospectively collected | 51 |
older patients | 51 |
also seen | 51 |
proliferative activity | 51 |
central venous | 51 |
significant association | 50 |
likely due | 50 |
will allow | 50 |
postoperative complication | 50 |
cells mm | 50 |
relatively high | 50 |
tumor cell | 50 |
body temperature | 50 |
interstitial pneumonia | 50 |
sars coronavirus | 50 |
inferior vena | 50 |
health status | 50 |
blood donation | 50 |
secondary attack | 50 |
drug administration | 50 |
upper quadrant | 50 |
time points | 50 |
blast cells | 50 |
day mortality | 50 |
rare disease | 50 |
diff erences | 50 |
aortic arch | 50 |
lung parenchyma | 50 |
secondary case | 50 |
within weeks | 50 |
sentinel lymph | 50 |
basal cell | 50 |
patient outcomes | 50 |
better understanding | 50 |
first line | 50 |
urban areas | 50 |
active case | 50 |
severe infections | 50 |
cells showed | 50 |
pediatr radiol | 50 |
operative treatment | 50 |
malignant lesions | 50 |
celiac disease | 50 |
diamond princess | 50 |
external genitalia | 50 |
information regarding | 50 |
severe covid | 50 |
cord blood | 50 |
skin biopsy | 50 |
health service | 50 |
cystic lesions | 50 |
fl uid | 50 |
benign lesions | 50 |
sudden onset | 49 |
effi cacy | 49 |
community cases | 49 |
artery disease | 49 |
health emergency | 49 |
cardiovascular disease | 49 |
operative management | 49 |
less invasive | 49 |
leading cause | 49 |
complete remission | 49 |
endemic areas | 49 |
rate among | 49 |
chronic inflammatory | 49 |
genetic analysis | 49 |
normal limits | 49 |
lower extremities | 49 |
human infection | 49 |
ebola epidemic | 49 |
may indicate | 49 |
three times | 49 |
peptic ulcer | 49 |
blood cultures | 49 |
streptococcus pneumoniae | 49 |
thrombocytopenic purpura | 49 |
diaphragmatic hernia | 49 |
randomly selected | 49 |
primary tumors | 49 |
mathematical modelling | 49 |
immune responses | 49 |
data will | 49 |
new zealand | 49 |
controlled trials | 49 |
row ct | 49 |
cases without | 49 |
exclusion criteria | 49 |
clinical relevance | 49 |
jp purpose | 49 |
malignant tumors | 49 |
fl ow | 49 |
cell type | 49 |
nissen fundoplication | 49 |
different levels | 49 |
slice ct | 49 |
water supply | 49 |
descriptive study | 49 |
among cases | 49 |
average temperature | 49 |
chronic hepatitis | 49 |
mouse model | 49 |
clinical follow | 49 |
syndromic surveillance | 49 |
center background | 49 |
coronavirus outbreak | 49 |
malignant cells | 49 |
rare entity | 49 |
inflammatory cells | 49 |
suspect cases | 48 |
much lower | 48 |
eff ect | 48 |
study demonstrates | 48 |
important factor | 48 |
viral rna | 48 |
chronic granulomatous | 48 |
information systems | 48 |
clinical picture | 48 |
four different | 48 |
histopathological examination | 48 |
systemic lupus | 48 |
cell function | 48 |
cerebrospinal fluid | 48 |
neurological symptoms | 48 |
patient showed | 48 |
infected person | 48 |
initial diagnosis | 48 |
muscle actin | 48 |
classified according | 48 |
ground glass | 48 |
extracellular matrix | 48 |
data show | 48 |
affected patients | 48 |
converting enzyme | 48 |
may reduce | 48 |
days prior | 48 |
th march | 48 |
two radiologists | 48 |
tumor progression | 48 |
face masks | 48 |
lymphocyte count | 48 |
cases due | 48 |
cell numbers | 48 |
epidemic models | 48 |
first patient | 48 |
poor outcome | 48 |
patients whose | 48 |
may need | 48 |
preventive measures | 48 |
patient group | 48 |
last months | 48 |
posted june | 48 |
bei der | 48 |
upper lobe | 48 |
severe symptoms | 47 |
four months | 47 |
toxic shock | 47 |
significantly greater | 47 |
model parameters | 47 |
using data | 47 |
embedded tissue | 47 |
oxygen saturation | 47 |
diagnostic yield | 47 |
may affect | 47 |
contrast material | 47 |
months follow | 47 |
multidisciplinary approach | 47 |
growth factors | 47 |
wildlife rehabilitation | 47 |
laboratory testing | 47 |
protective effect | 47 |
node biopsy | 47 |
allergic diseases | 47 |
postoperative hospital | 47 |
malignant melanoma | 47 |
within one | 47 |
liver failure | 47 |
young patients | 47 |
reproduction numbers | 47 |
cases diagnosed | 47 |
cell lymphopenia | 47 |
cases admitted | 47 |
surgical complications | 47 |
high expression | 47 |
renal involvement | 47 |
several factors | 47 |
animal model | 47 |
axillary lymph | 47 |
alkaline phosphatase | 47 |
disease may | 47 |
growth pattern | 47 |
tissue sections | 47 |
surgical repair | 46 |
neoadjuvant chemotherapy | 46 |
external fixation | 46 |
key role | 46 |
nerve palsy | 46 |
histological findings | 46 |
renal biopsy | 46 |
outpatient clinic | 46 |
weighted imaging | 46 |
randomized controlled | 46 |
laboratory results | 46 |
patients using | 46 |
high number | 46 |
limited number | 46 |
basal ganglia | 46 |
household size | 46 |
diffuse alveolar | 46 |
preliminary data | 46 |
containment measures | 46 |
staging system | 46 |
health surveillance | 46 |
relative risk | 46 |
patient management | 46 |
successful treatment | 46 |
well defined | 46 |
usually associated | 46 |
ductal carcinoma | 46 |
new method | 46 |
ex vivo | 46 |
infected population | 46 |
mitral valve | 46 |
case data | 46 |
radial head | 46 |
mesorectal excision | 46 |
many years | 46 |
liver biopsy | 46 |
symptomatic transmission | 46 |
supine position | 46 |
affected individuals | 46 |
pulmonary fibrosis | 46 |
reported confirmed | 46 |
incision laparoscopic | 46 |
data available | 46 |
prone position | 46 |
histological diagnosis | 46 |
relatively small | 46 |
approximately one | 46 |
colorectal carcinoma | 46 |
short time | 46 |
well described | 46 |
chest radiography | 46 |
pediatric radiologists | 46 |
cell differentiation | 46 |
acute care | 46 |
distant metastases | 46 |
may increase | 46 |
using two | 46 |
major trauma | 46 |
cases occurred | 46 |
th ese | 45 |
will need | 45 |
pancreatic duct | 45 |
infected pneumonia | 45 |
severely injured | 45 |
epidemic model | 45 |
west africa | 45 |
text introduction | 45 |
posterior fossa | 45 |
diff erent | 45 |
transcription factor | 45 |
several years | 45 |
fi bers | 45 |
single incision | 45 |
serum creatinine | 45 |
studies suggest | 45 |
days post | 45 |
small sample | 45 |
tumor necrosis | 45 |
type diabetes | 45 |
normal saline | 45 |
may appear | 45 |
classification system | 45 |
data regarding | 45 |
total mesorectal | 45 |
image analysis | 45 |
endoscopic surgery | 45 |
cells may | 45 |
nursing homes | 45 |
wall thickness | 45 |
institutional review | 45 |
growth rates | 45 |
time consuming | 45 |
infectious individuals | 45 |
life threatening | 45 |
increased number | 45 |
barr virus | 45 |
severe neurological | 45 |
low number | 45 |
allowed us | 45 |
mm slice | 45 |
ct examinations | 45 |
single institution | 45 |
early postoperative | 45 |
left lateral | 45 |
coronary arteries | 45 |
negative patients | 45 |
well documented | 45 |
visual analogue | 45 |
teaching hospital | 45 |
node involvement | 45 |
case management | 45 |
blood donations | 45 |
grade dysplasia | 45 |
high degree | 45 |
protective measures | 45 |
rectal prolapse | 44 |
closely related | 44 |
vital signs | 44 |
frozen section | 44 |
compartment syndrome | 44 |
care providers | 44 |
disease free | 44 |
severe complications | 44 |
previously published | 44 |
spermatic cord | 44 |
distal gastrectomy | 44 |
treatment modalities | 44 |
significant proportion | 44 |
zika virus | 44 |
using standard | 44 |
left ventricular | 44 |
surgical patients | 44 |
correlation coefficients | 44 |
allergic patients | 44 |
diagnostic tests | 44 |
lower lobe | 44 |
vertical transmission | 44 |
cardiac arrest | 44 |
phase ii | 44 |
patients included | 44 |
alveolar damage | 44 |
outcome measures | 44 |
ultrasound examination | 44 |
male presented | 44 |
human genetics | 44 |
statistical difference | 44 |
comparative study | 44 |
age distribution | 44 |
positive rate | 44 |
male pseudohermaphroditism | 44 |
liver enzymes | 44 |
without complications | 44 |
head injury | 44 |
disease outbreak | 44 |
took place | 44 |
clinical cases | 44 |
last year | 44 |
altered mental | 44 |
enhanced ct | 44 |
renal tumors | 44 |
mesenteric artery | 44 |
volume rendering | 44 |
daily new | 44 |
marrow biopsy | 44 |
basic reproductive | 44 |
two types | 44 |
testicular descent | 44 |
communicable disease | 44 |
common clinical | 44 |
congenital anomalies | 44 |
clinical setting | 44 |
hypogonadotropic hypogonadism | 44 |
will provide | 44 |
control strategies | 44 |
risk patients | 44 |
distal pancreatectomy | 44 |
fatal respiratory | 44 |
molecular weight | 44 |
task force | 44 |
may become | 43 |
years later | 43 |
mitigation strategies | 43 |
chronic disease | 43 |
blunt abdominal | 43 |
pue case | 43 |
dengue fever | 43 |
affected countries | 43 |
strong correlation | 43 |
chronic renal | 43 |
low incidence | 43 |
health facilities | 43 |
diffi cult | 43 |
mucous membranes | 43 |
laboratory confirmation | 43 |
two thirds | 43 |
based approach | 43 |
inner ear | 43 |
health professionals | 43 |
case control | 43 |
biliary tract | 43 |
competing interests | 43 |
major cause | 43 |
seven cases | 43 |
readily available | 43 |
influenza pandemic | 43 |
specific antibody | 43 |
clinical results | 43 |
tumor volume | 43 |
mean values | 43 |
hernia repairs | 43 |
expected number | 43 |
every weeks | 43 |
fold increase | 43 |
negative cases | 43 |
first report | 43 |
gene amplification | 43 |
cross sectional | 43 |
pulmonary arteries | 43 |
stromal cells | 43 |
immunocompromised patients | 43 |
group compared | 43 |
fresh frozen | 43 |
intramedullary nailing | 43 |
stromal tumors | 43 |
one patients | 43 |
immunoglobulin levels | 43 |
index patient | 43 |
severe asthma | 43 |
syndrome associated | 43 |
heterogeneous group | 43 |
abo rh | 43 |
limited data | 43 |
asthma symptoms | 43 |
care units | 43 |
reverse transcription | 42 |
test result | 42 |
nipah virus | 42 |
slightly higher | 42 |
needle biopsy | 42 |
surgical interventions | 42 |
laparoscopic procedures | 42 |
asthma control | 42 |
fibrin glue | 42 |
pediatric intensive | 42 |
increased incidence | 42 |
stage iii | 42 |
younger age | 42 |
targeted therapy | 42 |
histological type | 42 |
coronavirus pandemic | 42 |
shir model | 42 |
second patient | 42 |
cell adhesion | 42 |
family cluster | 42 |
delayed diagnosis | 42 |
recovery rate | 42 |
missense mutation | 42 |
malt lymphoma | 42 |
normal levels | 42 |
chronic obstructive | 42 |
ct showed | 42 |
infected persons | 42 |
secondary transmission | 42 |
pid patients | 42 |
invasive breast | 42 |
vascular malformations | 42 |
fluorescence imaging | 42 |
blood centers | 42 |
effective method | 42 |
assess whether | 42 |
primary immune | 42 |
tested negative | 42 |
conventional laparoscopic | 42 |
dry cough | 42 |
immunosuppressive therapy | 42 |
incubation periods | 42 |
rbc transfusion | 42 |
propensity score | 42 |
see section | 42 |
gene mutations | 42 |
large numbers | 42 |
review board | 42 |
signet ring | 42 |
high morbidity | 42 |
clinical immunology | 42 |
multidisciplinary team | 42 |
million cases | 42 |
room temperature | 42 |
twice daily | 42 |
data points | 42 |
identified using | 42 |
significant risk | 42 |
west african | 42 |
hemodynamically stable | 42 |
solar radiation | 42 |
preoperative diagnosis | 42 |
commonly seen | 42 |
various types | 42 |
complete resolution | 41 |
common symptoms | 41 |
androgen insensitivity | 41 |
fixed paraffin | 41 |
may reflect | 41 |
will continue | 41 |
eight cases | 41 |
valve replacement | 41 |
may vary | 41 |
live births | 41 |
renal masses | 41 |
paraffin sections | 41 |
causative agent | 41 |
positive staining | 41 |
coronavirus infections | 41 |
i i | 41 |
th percentile | 41 |
income countries | 41 |
classifi ed | 41 |
robotic system | 41 |
single port | 41 |
enhanced mr | 41 |
without evidence | 41 |
intraoperative complications | 41 |
care system | 41 |
face mask | 41 |
negative correlation | 41 |
higher proportion | 41 |
different age | 41 |
mean bmi | 41 |
less frequent | 41 |
clinically diagnosed | 41 |
mm collimation | 41 |
bladder neck | 41 |
active monitoring | 41 |
upper airway | 41 |
nasopharyngeal swab | 41 |
portal hypertension | 41 |
testicular microlithiasis | 41 |
infection may | 41 |
data obtained | 41 |
social media | 41 |
significantly shorter | 41 |
left sided | 41 |
emergency response | 41 |
inflammatory markers | 41 |
assisted surgery | 41 |
showed high | 41 |
performed within | 41 |
west nile | 41 |
blood type | 41 |
increased susceptibility | 41 |
yellow fever | 41 |
low anterior | 41 |
case scenario | 41 |
inflammatory disease | 41 |
injured patients | 41 |
among others | 41 |
groups according | 40 |
showed increased | 40 |
care homes | 40 |
asymptomatic infections | 40 |
mmol kg | 40 |
case i | 40 |
new covid | 40 |
open approach | 40 |
vascular injury | 40 |
multivariate logistic | 40 |
patient satisfaction | 40 |
icu admission | 40 |
analytics package | 40 |
detected cases | 40 |
pathogenic variants | 40 |
nasal congestion | 40 |
acute abdominal | 40 |
peanut allergy | 40 |
identify patients | 40 |
sectional study | 40 |
spin echo | 40 |
resource allocation | 40 |
solid organ | 40 |
platelet counts | 40 |
higher number | 40 |
less commonly | 40 |
new approach | 40 |
plasma exchange | 40 |
vein thrombosis | 40 |
lower limbs | 40 |
healthcare facilities | 40 |
tumor grade | 40 |
patient reported | 40 |
mean difference | 40 |
morbid obesity | 40 |
grade iv | 40 |
chest tube | 40 |
enhanced mri | 40 |
mean length | 40 |
pathogen concentration | 40 |
hemorrhagic shock | 40 |
oncological outcomes | 40 |
data sources | 40 |
frequently used | 40 |
appropriate treatment | 40 |
national level | 40 |
syncytial virus | 40 |
respiratory syncytial | 40 |
initial treatment | 40 |
healthy individuals | 40 |
cesarean section | 40 |
disease outbreaks | 40 |
scan revealed | 40 |
marrow transplantation | 40 |
influenza viruses | 40 |
risk group | 40 |
level i | 40 |
hearing aids | 40 |
waterborne illness | 40 |
medical conditions | 40 |
splenic artery | 40 |
disease onset | 40 |
ten cases | 40 |
serum level | 40 |
large bowel | 40 |
higher prevalence | 40 |
healthy children | 40 |
currently available | 40 |
etiologic agent | 40 |
treatment may | 39 |
evidence suggests | 39 |
evaluation revealed | 39 |
functional outcomes | 39 |
also possible | 39 |
detailed information | 39 |
observed data | 39 |
different clinical | 39 |
suspected case | 39 |
splice site | 39 |
postoperative outcomes | 39 |
series data | 39 |
give rise | 39 |
lymphocyte subsets | 39 |
epidemiological parameters | 39 |
market power | 39 |
reference laboratory | 39 |
one report | 39 |
cells per | 39 |
icu stay | 39 |
auf die | 39 |
outbreak investigation | 39 |
surgical cases | 39 |
local cases | 39 |
rotator cuff | 39 |
terminal ileum | 39 |
vascular endothelial | 39 |
case incidence | 39 |
policy makers | 39 |
da vinci | 39 |
frequently associated | 39 |
patients experienced | 39 |
school closures | 39 |
managed conservatively | 39 |
meningococcal disease | 39 |
high quality | 39 |
serum ige | 39 |
vascular invasion | 39 |
recurrent episodes | 39 |
robotic approach | 39 |
type iii | 39 |
lower urinary | 39 |
radiofrequency ablation | 39 |
stage ii | 39 |
splenic flexure | 39 |
patienten mit | 39 |
time point | 39 |
tumor tissue | 39 |
significant morbidity | 39 |
fever virus | 39 |
assisted laparoscopic | 39 |
matched controls | 39 |
specific treatment | 39 |
demographic characteristics | 39 |
muscle weakness | 39 |
bronchial asthma | 39 |
infect dis | 39 |
reported data | 39 |
several days | 39 |
clinical spectrum | 39 |
allergic asthma | 39 |
microvessel density | 39 |
group showed | 39 |
granulation tissue | 39 |
significant role | 39 |
fi brosis | 39 |
lung adenocarcinomas | 39 |
particulate matter | 39 |
pathogen reduction | 39 |
initial experience | 39 |
mr angiography | 39 |
invasive technique | 39 |
functional results | 39 |
elderly people | 39 |
frozen plasma | 39 |
underlying health | 39 |
patients also | 39 |
muscle cells | 39 |
gamma distribution | 39 |
radical cystectomy | 39 |
also noted | 39 |
hodgkin lymphoma | 39 |
breast cancers | 39 |
epidemic curves | 39 |
clinical manifestation | 38 |
revision surgery | 38 |
erectile function | 38 |
liver cirrhosis | 38 |
good clinical | 38 |
cell disease | 38 |
tumor suppressor | 38 |
low cd | 38 |
african ebola | 38 |
four groups | 38 |
botulinum toxin | 38 |
heterozygous mutations | 38 |
clinical severity | 38 |
reported deaths | 38 |
patient required | 38 |
observation period | 38 |
analysed using | 38 |
clinical specimens | 38 |
polyarteritis nodosa | 38 |
erectile dysfunction | 38 |
arterial blood | 38 |
elevated levels | 38 |
viral pneumonia | 38 |
site infection | 38 |
associated injuries | 38 |
last decade | 38 |
supplementary table | 38 |
adc values | 38 |
significant higher | 38 |
high sensitivity | 38 |
study will | 38 |
incidence rate | 38 |
initial phase | 38 |
statistical analyses | 38 |
low level | 38 |
patients operated | 38 |
parameter values | 38 |
cases identified | 38 |
th postoperative | 38 |
chronic pancreatitis | 38 |
case detection | 38 |
laparoscopic appendectomy | 38 |
robot assisted | 38 |
bronchoalveolar lavage | 38 |
actual number | 38 |
medical management | 38 |
supportive care | 38 |
suppressor gene | 38 |
demographic information | 38 |
function mutations | 38 |
term exposure | 38 |
provide information | 38 |
thyroid carcinoma | 38 |
adenovirus type | 38 |
high volume | 38 |
surgery patients | 38 |
several weeks | 38 |
rural areas | 38 |
alimentary lymphoma | 38 |
aortic valve | 38 |
renal transplant | 38 |
fungal infections | 38 |
icg fluorescence | 38 |
single dose | 38 |
healthy subjects | 38 |
ventral hernia | 38 |
treatment group | 38 |
quantitative analysis | 38 |
supply network | 38 |
secondary infections | 38 |
damage control | 38 |
bile ducts | 38 |
observational studies | 38 |
fatality ratio | 38 |
cured cases | 38 |
fatality risk | 38 |
incidence rates | 38 |
respiratory system | 38 |
thoracic surgery | 38 |
within minutes | 38 |
greater risk | 38 |
global pandemic | 38 |
categorical variables | 38 |
surgical team | 38 |
salivary glands | 38 |
renal artery | 38 |
samples collected | 38 |
adrenal hyperplasia | 38 |
identified cases | 38 |
renal dysfunction | 38 |
gene panel | 38 |
literature search | 37 |
basement membrane | 37 |
cancer cell | 37 |
upper extremity | 37 |
initial number | 37 |
york city | 37 |
advanced stage | 37 |
frequently observed | 37 |
canine lymphoma | 37 |
icu patients | 37 |
kidney injury | 37 |
news sentiment | 37 |
cox regression | 37 |
crucial role | 37 |
will present | 37 |
asymptomatic carriers | 37 |
cardiac disease | 37 |
food security | 37 |
failure rate | 37 |
results demonstrate | 37 |
pancreatic cancer | 37 |
conservative management | 37 |
positive result | 37 |
study using | 37 |
four weeks | 37 |
probably due | 37 |
commonly associated | 37 |
innate immune | 37 |
remains controversial | 37 |
present case | 37 |
esophageal cancer | 37 |
multiple sclerosis | 37 |
brain tumors | 37 |
term survival | 37 |
death cases | 37 |
significantly correlated | 37 |
cord injury | 37 |
control patients | 37 |
throat swab | 37 |
cases within | 37 |
organ dysfunction | 37 |
also included | 37 |
effi ciency | 37 |
standard treatment | 37 |
good correlation | 37 |
arterial phase | 37 |
hand hygiene | 37 |
year history | 37 |
consecutive days | 37 |
last two | 37 |
mass spectrometry | 37 |
familial cluster | 37 |
prospective cohort | 37 |
undergoing laparoscopic | 37 |
seven days | 37 |
common causes | 37 |
phase i | 37 |
paraesophageal hernia | 37 |
initial presentation | 37 |
new deaths | 37 |
asthmatic patients | 37 |
lymphoid cells | 37 |
analogue scale | 37 |
mean score | 37 |
first weeks | 37 |
studies showed | 37 |
point scale | 37 |
high index | 37 |
studies revealed | 37 |
medical faculty | 37 |
androgen receptor | 37 |
histopathological findings | 37 |
wbc count | 37 |
fracture healing | 37 |
individual cases | 37 |
histological grade | 37 |
average length | 37 |
national medical | 37 |
respiratory rate | 36 |
immune cells | 36 |
pelvic fractures | 36 |
short period | 36 |
penetrating trauma | 36 |
signifi cance | 36 |
allergic reaction | 36 |
trauma team | 36 |
critical role | 36 |
high rates | 36 |
initial cases | 36 |
human cases | 36 |
several months | 36 |
drug reactions | 36 |
histopathologic findings | 36 |
infl ammation | 36 |
positive case | 36 |
one hand | 36 |
like cells | 36 |
different stages | 36 |
worse prognosis | 36 |
pediatric patient | 36 |
graft placement | 36 |
potential secondary | 36 |
gene mutation | 36 |
laparoscopic right | 36 |
eleven patients | 36 |
ischemic stroke | 36 |
control policy | 36 |
study research | 36 |
group iii | 36 |
cerebral blood | 36 |
intraepithelial neoplasia | 36 |
rank test | 36 |
first hours | 36 |
higher compared | 36 |
retrospectively evaluated | 36 |
persistent asthma | 36 |
normal controls | 36 |
significantly better | 36 |
natural killer | 36 |
gastric carcinoma | 36 |
highly sensitive | 36 |
external fixator | 36 |
past decade | 36 |
renal transplantation | 36 |
skeletal muscle | 36 |
several times | 36 |
tract symptoms | 36 |
cancer cases | 36 |
bone lesions | 36 |
widely accepted | 36 |
tests per | 36 |
gastric wall | 36 |
infected travellers | 36 |
also significantly | 36 |
right kidney | 36 |
group consisted | 36 |
unknown origin | 36 |
gastrointestinal symptoms | 36 |
performed without | 36 |
previous study | 36 |
every case | 36 |
new technique | 36 |
operative pain | 36 |
parotid gland | 36 |
total protein | 36 |
dendritic cells | 36 |
blood services | 36 |
lung abscess | 36 |
saharan africa | 36 |
laparoscopic total | 36 |
significant change | 36 |
also identified | 36 |
greece objective | 36 |
light chain | 36 |
clinical use | 36 |
anterior wall | 36 |
specific antibodies | 36 |
necrosis factor | 36 |
apheresis platelets | 36 |
identified patients | 36 |
also evaluated | 36 |
differ significantly | 36 |
model fit | 36 |
malignant potential | 36 |
mm trocar | 36 |
using different | 35 |
mainly due | 35 |
left kidney | 35 |
american society | 35 |
invasive method | 35 |
near future | 35 |
death counts | 35 |
prospective studies | 35 |
surface area | 35 |
cell development | 35 |
myeloid leukemia | 35 |
total score | 35 |
two consecutive | 35 |
report two | 35 |
upper bound | 35 |
case duration | 35 |
princess cruise | 35 |
lessons learned | 35 |
organ injury | 35 |
different methods | 35 |
survival time | 35 |
neurological disease | 35 |
breast lesions | 35 |
sentiment analysis | 35 |
many people | 35 |
baseline characteristics | 35 |
different regions | 35 |
molecular testing | 35 |
blood transfusions | 35 |
health problem | 35 |
months prior | 35 |
bronchiolitis obliterans | 35 |
continuous variables | 35 |
laparoscopic colorectal | 35 |
human testis | 35 |
trauma centers | 35 |
influenza vaccine | 35 |
showed normal | 35 |
pleural effusions | 35 |
five days | 35 |
abscess formation | 35 |
false positives | 35 |
asthma severity | 35 |
mass effect | 35 |
pathogenic variant | 35 |
mit einem | 35 |
health measures | 35 |
first three | 35 |
outbreak response | 35 |
fi stula | 35 |
viral hemorrhagic | 35 |
molecular analysis | 35 |
water treatment | 35 |
skull base | 35 |
rare condition | 35 |
comparative analysis | 35 |
also occur | 35 |
endothelial growth | 35 |
clinical parameters | 35 |
digital subtraction | 35 |
wild type | 35 |
ct scanner | 35 |
may improve | 35 |
showed significantly | 35 |
large proportion | 35 |
marrow edema | 35 |
several cases | 35 |
twenty patients | 35 |
data indicate | 35 |
price increases | 35 |
therapeutic approach | 35 |
early transmission | 35 |
resolution ct | 35 |
food allergens | 35 |
signaling pathway | 35 |
developed symptoms | 35 |
monoclonal gammopathy | 35 |
type iv | 35 |
recurrent respiratory | 35 |
respiratory diseases | 35 |
surgical pathology | 35 |
symptomatic individuals | 35 |
risk reduction | 35 |
amino acids | 35 |
health commission | 35 |
hospital admissions | 35 |
study suggests | 35 |
infectious agent | 35 |
biliary tree | 35 |
papillary carcinoma | 35 |
ethics committee | 35 |
every year | 35 |
measures taken | 35 |
relatively common | 35 |
nan title | 35 |
brachial plexus | 35 |
routine use | 34 |
asymptomatic individuals | 34 |
south african | 34 |
first day | 34 |
side eff | 34 |
early identification | 34 |
epidemic growth | 34 |
definitive treatment | 34 |
data may | 34 |
inhalational anthrax | 34 |
robotic assisted | 34 |
high percentage | 34 |
testicular parenchyma | 34 |
clinical laboratory | 34 |
beta regression | 34 |
distal radius | 34 |
general anaesthesia | 34 |
rectal resection | 34 |
also associated | 34 |
therapeutic options | 34 |
tumor stage | 34 |
industrialized countries | 34 |
higher mortality | 34 |
patients years | 34 |
patients met | 34 |
time frame | 34 |
male infertility | 34 |
international spread | 34 |
including patients | 34 |
effective dose | 34 |
stromal tumor | 34 |
infection fatality | 34 |
treatment strategies | 34 |
medical literature | 34 |
radiologic findings | 34 |
kidney transplantation | 34 |
wind speed | 34 |
cystic lesion | 34 |
infectious complications | 34 |
pain control | 34 |
clinical phenotype | 34 |
bone formation | 34 |
located within | 34 |
receiver operating | 34 |
new infections | 34 |
drain placement | 34 |
cryptorchid testes | 34 |
receptor gene | 34 |
hospital discharge | 34 |
left lower | 34 |
cases included | 34 |
infection prevention | 34 |
significant changes | 34 |
clinical disease | 34 |
factor viii | 34 |
publicly reported | 34 |
increased significantly | 34 |
laparoscopic liver | 34 |
sample collection | 34 |
published data | 34 |
different scenarios | 34 |
results will | 34 |
lymphocytic leukemia | 34 |
major role | 34 |
host disease | 34 |
patients suffered | 34 |
th week | 34 |
ten years | 34 |
response rates | 34 |
free fluid | 34 |
often difficult | 34 |
recent study | 34 |
malignant lymphoma | 34 |
serious complications | 34 |
complications related | 34 |
giant cell | 34 |
estimated using | 34 |
vascular anomalies | 34 |
compared using | 34 |